CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions

DRUG: CLN-049

Sponsor

Cullinan Therapeutics Inc.